ABT
Income statement / Annual
Last year (2023), Abbott Laboratories's total revenue was $40.11 B,
a decrease of 8.12% from the previous year.
In 2023, Abbott Laboratories's net income was $5.72 B.
See Abbott Laboratories’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$40.11 B
|
$43.65 B
|
$43.08 B
|
$34.61 B
|
$31.90 B
|
$30.58 B
|
$27.39 B
|
$20.85 B
|
$20.41 B
|
$20.25 B
|
| Cost of Revenue |
$17.98 B |
$19.14 B |
$18.54 B |
$15.00 B |
$13.23 B |
$12.71 B |
$12.34 B |
$9.02 B |
$8.75 B |
$9.22 B |
| Gross Profit |
$22.13 B |
$24.51 B |
$24.54 B |
$19.61 B |
$18.67 B |
$17.87 B |
$15.05 B |
$11.83 B |
$11.66 B |
$11.03 B |
| Gross Profit Ratio |
0.55 |
0.56 |
0.57 |
0.57 |
0.59 |
0.58 |
0.55 |
0.57 |
0.57 |
0.54 |
| Research and Development
Expenses |
$2.74 B
|
$2.89 B
|
$2.74 B
|
$2.42 B
|
$2.44 B
|
$2.30 B
|
$2.24 B
|
$1.42 B
|
$1.41 B
|
$1.35 B
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9.74 B
|
$9.12 B
|
$6.67 B
|
$6.79 B
|
$6.53 B
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$10.95 B
|
$11.25 B
|
$11.32 B
|
$9.70 B
|
$9.77 B
|
$9.74 B
|
$9.12 B
|
$6.67 B
|
$6.79 B
|
$6.53 B
|
| Other Expenses |
$479.00 M |
$2.01 B |
$2.05 B |
$2.13 B |
$1.94 B |
$139.00 M |
$1.25 B |
-$945.00 M |
$281.00 M |
-$14.00 M |
| Operating Expenses |
$15.66 B |
$16.15 B |
$16.11 B |
$14.25 B |
$14.14 B |
$14.22 B |
$13.33 B |
$8.64 B |
$8.79 B |
$8.43 B |
| Cost And Expenses |
$33.63 B |
$35.29 B |
$34.65 B |
$29.25 B |
$27.37 B |
$26.93 B |
$25.66 B |
$17.67 B |
$17.54 B |
$17.65 B |
| Interest Income |
$385.00 M |
$183.00 M |
$43.00 M |
$46.00 M |
$94.00 M |
$105.00 M |
$124.00 M |
$99.00 M |
$105.00 M |
$77.00 M |
| Interest Expense |
$637.00 M |
$375.00 M |
$490.00 M |
$500.00 M |
$576.00 M |
$721.00 M |
$780.00 M |
$332.00 M |
$58.00 M |
$73.00 M |
| Depreciation &
Amortization |
$3.24 B
|
$3.27 B
|
$3.54 B
|
$3.33 B
|
$3.01 B
|
$3.28 B
|
$3.02 B
|
$1.35 B
|
$601.00 M
|
$555.00 M
|
| EBITDA |
$10.59 B
|
$10.70 B
|
$10.75 B
|
$7.59 B
|
$6.66 B
|
$5.97 B
|
$4.95 B
|
$2.79 B
|
$3.75 B
|
$3.14 B
|
| EBITDA Ratio |
0.26 |
0.25 |
0.25 |
0.22 |
0.21 |
0.2 |
0.18 |
0.13 |
0.18 |
0.16 |
| Operating Income Ratio
|
0.16
|
0.19
|
0.2
|
0.15
|
0.14
|
0.12
|
0.06
|
0.15
|
0.14
|
0.13
|
| Total Other
Income/Expenses Net |
$438.00 M
|
-$56.00 M
|
-$214.00 M
|
-$389.00 M
|
-$455.00 M
|
-$56.00 M
|
$1.29 B
|
-$1.44 B
|
$374.00 M
|
-$8.00 M
|
| Income Before Tax |
$6.66 B |
$8.31 B |
$8.21 B |
$4.97 B |
$4.08 B |
$2.87 B |
$2.23 B |
$1.41 B |
$3.18 B |
$2.52 B |
| Income Before Tax Ratio
|
0.17
|
0.19
|
0.19
|
0.14
|
0.13
|
0.09
|
0.08
|
0.07
|
0.16
|
0.12
|
| Income Tax Expense |
$941.00 M |
$1.37 B |
$1.14 B |
$497.00 M |
$390.00 M |
$539.00 M |
$1.88 B |
$350.00 M |
$577.00 M |
$797.00 M |
| Net Income |
$5.72 B |
$6.93 B |
$7.07 B |
$4.50 B |
$3.69 B |
$2.37 B |
$477.00 M |
$1.40 B |
$4.42 B |
$2.28 B |
| Net Income Ratio |
0.14 |
0.16 |
0.16 |
0.13 |
0.12 |
0.08 |
0.02 |
0.07 |
0.22 |
0.11 |
| EPS |
3.3 |
3.94 |
3.97 |
2.52 |
2.07 |
1.35 |
0.27 |
0.95 |
3 |
1.51 |
| EPS Diluted |
3.26 |
3.91 |
3.94 |
2.5 |
2.06 |
1.34 |
0.27 |
0.94 |
2.94 |
1.5 |
| Weighted Average Shares
Out |
$1.74 B
|
$1.75 B
|
$1.78 B
|
$1.77 B
|
$1.77 B
|
$1.76 B
|
$1.74 B
|
$1.47 B
|
$1.47 B
|
$1.51 B
|
| Weighted Average Shares
Out Diluted |
$1.75 B
|
$1.76 B
|
$1.79 B
|
$1.79 B
|
$1.78 B
|
$1.77 B
|
$1.75 B
|
$1.48 B
|
$1.51 B
|
$1.53 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
